6000! That's the number of associates in the Novartis Institutes for BioMedical Research (NIBR). This division is the innovation engine of Novartis, focusing on powerful new technologies that have the potential to help produce therapeutic breakthroughs for patients. NIBR Biologics Center (NBC) builds the biologics pipeline in collaboration with NIBR Disease Areas and Platforms via a breadth of technologies for discovery of antibody, protein and gene therapy-based therapeutics.
We are seeking a Principal Scientist specialized in viral gene therapies with an emphasis on AAV to join the Biotherapeutic Engineering and Gene Therapy (BEGT) group within NBC in Cambridge, Massachusetts. The BEGT group drives a diverse portfolio of modalities including therapeutic proteins, multi-specific antibodies, CAR-T, RNA therapeutics and AAV. Through innovative and rational protein design as well as cell and viral engineering, the BEGT group works collaboratively within NIBR to broaden the use of biologics into therapeutic applications where conventional antibodies have limitations.
Your key responsibilities are, but not limited to: * Design and perform experiments independently to address key scientific questions in the AAV gene therapy field. * Bridge eukaryotic gene expression expertise, conjugation and capsid engineering to bring the next generation of gene delivery platforms into the pipeline. * Work collaboratively to lead synthetic biology activities and contribute to gene therapy platform and pipeline. * Establish in vitro cell based assays to support gene therapy research. * Contribute to NBC's viral production activities at research scale (discovery through NHP). * Collaborate with Disease Area colleagues to address unmet technology needs with well-designed experiments and execution.